Review. Clinical pharmacokinetics of bortezomib

Dominique Levêque; Marie Christine Monteiro Carvalho; Frederic Maloisel

Review. Clinical pharmacokinetics of bortezomib

In Vivo. 2007 Mar-Apr;21(2):273-8.

Authors

Dominique Levêque¹, Marie Christine Monteiro Carvalho, Frederic Maloisel

Affiliation

¹ Hôpital de Hautepierre, Pharmacie, 67000 Strasbourg, France. dominique.leveque@chru-strasbourg.fr

PMID: 17436576

Abstract

This review presents the clinical pharmacokinetics of bortezomib. Aspects regarding metabolism, pharmacodynamics and drug interactions are also discussed.

Publication types

Review

MeSH terms

Antineoplastic Agents / pharmacokinetics*
Antineoplastic Agents / therapeutic use
Antineoplastic Agents / toxicity
Boronic Acids / pharmacokinetics*
Boronic Acids / therapeutic use
Boronic Acids / toxicity
Bortezomib
Clinical Trials, Phase I as Topic
Clinical Trials, Phase II as Topic
Humans
Kidney / metabolism
Kidney / pathology
Kinetics
Lymphoma, Non-Hodgkin / drug therapy*
Multiple Myeloma / drug therapy*
Pyrazines / pharmacokinetics*
Pyrazines / therapeutic use
Pyrazines / toxicity

Substances

Antineoplastic Agents
Boronic Acids
Pyrazines
Bortezomib